[Studies on substances in the benzofuran group. 43. Angiotrophic, anti-inflammatory and fibrinolytic properties of benzarone].
D000109:Acetylcholine / Q000037:antagonists & inhibitors; D000818:Animals; D000893:Anti-Inflammatory Agents / Q000494:pharmacology*; D001572:Benzofurans / Q000494:pharmacology* / Q000627:therapeutic use; D001777:Blood Coagulation / Q000187:drug effects*; D001920:Bradykinin / Q000037:antagonists & inhibitors; D002199:Capillary Permeability / Q000187:drug effects*; D002200:Capillary Resistance / Q000187:drug effects*; D002908:Chronic Disease; D003864:Depression, Chemical; D004285:Dogs; D004487:Edema / Q000517:prevention & control; D004837:Epinephrine / Q000037:antagonists & inhibitors; D005260:Female; D005342:Fibrinolysis / Q000187:drug effects*; D005343:Fibrinolytic Agents / Q000494:pharmacology*; D006168:Guinea Pigs; D006634:Histamine H1 Antagonists / Q000494:pharmacology; D009164:Mycobacterium Infections / Q000517:prevention & control; D009638:Norepinephrine / Q000037:antagonists & inhibitors; D011817:Rabbits; D051381:Rats; D012702:Serotonin Antagonists; D013268:Stimulation, Chemical; D014652:Vascular Diseases / Q000188:drug therapy
D000893:Anti-Inflammatory Agents; D001572:Benzofurans; D005343:Fibrinolytic Agents; D006634:Histamine H1 Antagonists; D012702:Serotonin Antagonists; D000109:Acetylcholine; D001920:Bradykinin; D009638:Norepinephrine; D004837:Epinephrine
Recherches dans la série des benzofurannes. 43. Propriétés angéiotrophiques, antiinflammatoires et fibrinolytiques de la benzarone.